Transarterial chemoembolization with DC Bead LUMI™ radiopaque beads for primary liver cancer treatment: preliminary experience

Camillo Aliberti, Riccardo Carandina, Donatella Sarti, Enrico Pizzirani, Gaetano Ramondo, Umberto Cillo, Stefano Guadagni, Giammaria Fiorentini

Research output: Contribution to journalArticle

Abstract

AIM: Primary objectives of the study were to assess the safety of transarterial chemoembolization (TACE) using DC Bead LUMI™ for the treatment of hepatocellular carcinoma and beads distribution after TACE.

PATIENTS/METHODS: This was a prospective observational cohort study. The study included 44 hepatocellular carcinoma patients who were treated with TACE using DC Bead LUMI. Beads distribution was monitored 1 h after TACE by CT scan.

RESULTS: TACE had no intraprocedural complications. Observed side effects were of mild intensity and included pain in 5 (11%), fever in 4 (9%) and vomiting in 2 (5%) patients. Most patients (89%) reported no adverse event. Non-target distribution was observed in only two cases (5%).

CONCLUSION: DC Bead LUMI allowed assessing in real time their distribution. This could prevent non-target infusion and reduce toxicity.

Original languageEnglish
Pages (from-to)2243-2252
Number of pages10
JournalFuture Oncology
Volume13
Issue number25
DOIs
Publication statusPublished - Oct 2017

Keywords

  • Journal Article

Fingerprint Dive into the research topics of 'Transarterial chemoembolization with DC Bead LUMI™ radiopaque beads for primary liver cancer treatment: preliminary experience'. Together they form a unique fingerprint.

Cite this